Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting GlobeNewswire - Sun Apr 19, 5:00PM CDT

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly...

XENE : 55.24 (-0.31%)
Xenon to Present at Upcoming Investor Conferences GlobeNewswire - Wed Apr 15, 7:30AM CDT

VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 55.24 (-0.31%)
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting GlobeNewswire - Tue Apr 7, 7:30AM CDT

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Thu Mar 12, 3:01PM CDT

VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering GlobeNewswire - Tue Mar 10, 9:39PM CDT

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals Announces Proposed Public Offering GlobeNewswire - Mon Mar 9, 3:01PM CDT

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

XENE : 55.24 (-0.31%)
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) GlobeNewswire - Mon Mar 9, 6:00AM CDT

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006)...

XENE : 55.24 (-0.31%)
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 GlobeNewswire - Sun Mar 8, 1:00PM CDT

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...

XENE : 55.24 (-0.31%)
Xenon Pharmaceuticals: Q4 Earnings Snapshot AP - Thu Feb 26, 4:04PM CST

Xenon Pharmaceuticals: Q4 Earnings Snapshot

XENE : 55.24 (-0.31%)
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Feb 26, 3:01PM CST

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with...

XENE : 55.24 (-0.31%)

Barchart Exclusives

Intel Earnings Confirm CPU Demand Is Outpacing Supply, But Does the Company Really Have an Edge? Barchart - 23 minutes ago
Donald Trump's investment in Intel was timely, but can Intel solve its execution problem? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.